الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Over the past 20 years obesity has become a worldwide concern of frightening proportion. The treatment of obesity requires modulation of both energy intake and energy expenditure, and pharmaceutical treatments are being developed to complement the traditional means of dietary restriction and exercise.
Between the 1930 and the present, more than a half dozen drugs were widely prescribed to obese patients for a period, then later removed from the market due to the serious adverse events, the first attempt to develop an anti-obesity drug can be dated to 1800s, when, based on its effectiveness for hypothyroidism, thyroid hormone became a popular treatment for obesity in euthyroid p eople. It had a modest effect, but produced the symptoms of hyperthyroidism as a side effect, such as palpitations and difficulty sleeping.
Orlistat 120 mg was approved as a prescription product by the FDA in 1999 for obesity management in conjunction with a reduced caloric diet, and to reduce the risk of regaining weight after prior weight loss. Orlistat was purchased as a capsule with a trade name (Xenical) manufactured by Hoffmann-La Roche, Germany. In 2007, orlistat 60 mg was approved, under the brand name (Alli), for an over-the-counter (OTC) use for weight loss in overweight adults, 18 years and older, in conjunction with a reduced-calorie and low-fat diet. Currently, orlistat is approved for marketing in approximately 100 countries.
Many studies have been done to examine the adverse effects of administration of orlistat on different organs such as kidney, liver, GIT, spleen, pancreas, heart…etc.
The aim of this study was to evaluate the effect of oral administration of orlistat in different doses and in different durations on parotid and submandibular salivary glands of adult male albino rats.
The study was carried out on sixty healthy adult male albino rats of average weight (150 – 180) grams.